State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer - European Medical Journal
×

Browse

State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer

| Download as | PDF
Authors:
*Elena Castro,1,2 Nuria Romero,1,2 David Olmos1,2
Disclosure:

No potential conflict of interest.

Received:
22.05.14
Accepted:
09.09.14
Citation
EMJ Oncol. ;2[1]:100-105.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

Prostate cancer (PrCa) is the most common cancer type in men in developed countries. In the last few years, a dramatic change has occurred in the understanding of castration-resistant PrCa which has led to the development of new drugs that have an impact on patient survival. This review summarises the recent advances in the management of the disease.

Please view the full content in the pdf above.